[{"id":"2dd784c3-2556-4e8f-858c-e43a2f1be9da","acronym":"realMIND","url":"https://clinicaltrials.gov/study/NCT04981795","created_at":"2021-07-29T14:53:08.563Z","updated_at":"2024-07-02T16:34:26.241Z","phase":"","brief_title":"realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL","source_id_and_acronym":"NCT04981795 - realMIND","lead_sponsor":"Incyte Corporation","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation • BCL2 translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-06-13"},{"id":"183d1ef7-c946-4ec1-95d1-e0802e6a3e7c","acronym":"EPCORE NHL-6","url":"https://clinicaltrials.gov/study/NCT05451810","created_at":"2022-07-11T11:54:54.294Z","updated_at":"2024-07-02T16:34:58.948Z","phase":"Phase 2","brief_title":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma","source_id_and_acronym":"NCT05451810 - EPCORE NHL-6","lead_sponsor":"Genmab","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 08/29/2027","primary_completion_date":" 08/29/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-04"},{"id":"19564d20-8ce4-4508-8710-2dc03972dfff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05201248","created_at":"2022-01-21T14:58:14.779Z","updated_at":"2024-07-02T16:34:59.188Z","phase":"Phase 1","brief_title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05201248","lead_sponsor":"Genmab","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epkinly (epcoritamab-bysp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 12/13/2024","primary_completion_date":" 12/13/2024","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-06-04"},{"id":"700dc8c9-7994-4f0c-9f97-a10c4b36a1dd","acronym":"GO43075","url":"https://clinicaltrials.gov/study/NCT04980222","created_at":"2021-07-28T19:52:29.789Z","updated_at":"2024-07-02T16:34:58.915Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04980222 - GO43075","lead_sponsor":"Hoffmann-La Roche","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD20 positive • MYC expression • BCL6 translocation","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • MYC expression • BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-04"},{"id":"acc063ee-1af6-4a9d-b0aa-6e09d71310a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231877","created_at":"2021-01-18T20:35:12.972Z","updated_at":"2024-07-02T16:35:07.534Z","phase":"Phase 1","brief_title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma","source_id_and_acronym":"NCT04231877","lead_sponsor":"University of Washington","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Suspended","enrollment":" Enrollment 50","initiation":"Initiation: 10/27/2020","start_date":" 10/27/2020","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-25"},{"id":"88f42f2b-3280-4f89-8f51-0e7028896643","acronym":"BELLWAVE-001","url":"https://clinicaltrials.gov/study/NCT03162536","created_at":"2021-01-18T15:35:37.913Z","updated_at":"2024-07-02T16:35:15.719Z","phase":"Phase 1/2","brief_title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","source_id_and_acronym":"NCT03162536 - BELLWAVE-001","lead_sponsor":"ArQule, Inc., a subsidiary of Merck Sharp \u0026 Dohme LLC, a subsidiary of Merck \u0026 Co., Inc. (Rahway, NJ USA)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BTK mutation • BCL6 translocation • BTK C481","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BTK mutation • BCL6 translocation • BTK C481"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nemtabrutinib (MK-1026)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 06/26/2017","start_date":" 06/26/2017","primary_txt":" Primary completion: 09/12/2025","primary_completion_date":" 09/12/2025","study_txt":" Completion: 09/12/2025","study_completion_date":" 09/12/2025","last_update_posted":"2024-03-08"},{"id":"ab6d3749-1aae-4800-9afd-f5306727287f","acronym":"PLACARD","url":"https://clinicaltrials.gov/study/NCT03873025","created_at":"2021-01-18T19:05:49.079Z","updated_at":"2025-02-25T16:08:58.883Z","phase":"Phase 1/2","brief_title":"A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT03873025 - PLACARD","lead_sponsor":"University College, London","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • zabinostat (CXD101)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2021-08-17"},{"id":"3e8d61ce-5436-4030-a690-3833bf9a750d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01742988","created_at":"2021-01-18T07:38:21.868Z","updated_at":"2024-07-02T16:36:30.660Z","phase":"Phase 1","brief_title":"Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma","source_id_and_acronym":"NCT01742988","lead_sponsor":"Curis, Inc.","biomarkers":" MYC • BCL2 • BCL6 • CREBBP","pipe":" | ","alterations":" MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation","tags":["MYC • BCL2 • BCL6 • CREBBP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • fimepinostat (CUDC-907)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 10/09/2020","primary_completion_date":" 10/09/2020","study_txt":" Completion: 10/09/2020","study_completion_date":" 10/09/2020","last_update_posted":"2021-05-06"},{"id":"7985c998-0030-47ca-9932-3dd8bf49ef20","acronym":"MicroBLITZ","url":"https://clinicaltrials.gov/study/NCT03920631","created_at":"2021-01-18T19:17:28.026Z","updated_at":"2024-07-02T16:36:32.966Z","phase":"Phase 1","brief_title":"Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas","source_id_and_acronym":"NCT03920631 - MicroBLITZ","lead_sponsor":"Ahmed Galal, MD","biomarkers":" BCL2 • BCL6 • HLA-DRB1","pipe":" | ","alterations":" BCL6 translocation","tags":["BCL2 • BCL6 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 03/15/2023","primary_completion_date":" 03/15/2023","study_txt":" Completion: 05/15/2023","study_completion_date":" 05/15/2023","last_update_posted":"2021-03-23"}]